Clinical Trial Update: Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

View source ↗

Summary

A completed clinical trial evaluates the burden of non-adherence to nintedanib in patients with idiopathic pulmonary fibrosis. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED | Results posted: 2024-10-01